Recent Research: Atopic Dermatitis Treatment Market Analysis to 2019

Atopic dermatitis (AD) is a type of skin disorder in which the skin becomes dry, itchy and inflamed. Scratching of the skin leads to redness, swelling, scaling, cracking, weeping and crusting. Though, this condition is most common in infants and children, also affects adult population.

AD is considered as idiopathic, a disease without a known cause, and is likely to be caused by both genetic as well as environmental factors. Many persons with AD have been found with a family history of atopy. People living in dry climate are more likely to get affected. Generally, people with AD develop asthma and hay fever.

Obtain Report Details @ https://www.transparencymarketresearch.com/atopic-dermatitis-treatment-market.html

Topical steroids are currently the mainstay of treatment of atopic dermatitis and hold the largest segment of the overall atopic dermatitis treatment market. A five minute lukewarm baths followed by the application of a moisturizer is also beneficial in treating patients suffering from AD. Immunomodulators such as tacrolimus and Pimecrolimus are too used to treat AD. The global market for atopic dermatitis treatment will be majorly driven by new product launch in coming years.

The anticipated launch of dupilumab, a monoclonal antibody being developed by Sanofi and Regeneron Pharmaceuticals, Inc. for treating atopic diseases is expected to play a major role in driving the growth of atopic dermatitis treatment market across the globe. Side effects associated with drugs used in the treatment of AD are one of the major reasons hampering the market growth. The market offers opportunities for companies engaged in developing novel systemic therapies as there is a considerable need for medications with enhanced safety and efficacy profiles.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2125

The number of patients suffering from atopic dermatitis has significantly increased during the last three decades. According to the National Eczema Association (NEA), AD affects nearly 10% to 20% of infants in the U.S. In Asia-Pacific, India and China are the major countries accounting for a larger proportion of the total prevalent cases around the globe. Some of the key players operating in the market for atopic dermatitis are Astellas Pharma, Anacor Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc. and Meda AB.

Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=2125<ype=S

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.